ArticleInternational journal of pharmaceutics2008
Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
Article in International journal of pharmaceutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 67 citations in OpenAlex.
- Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.Drug delivery and translational research · 2024Article
- Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.Research square · 2023Article
- Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers.Pharmaceutics · 2022Article
- Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018Article
- Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.Chemical Society reviews · 2018Review
- Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.International journal of pharmaceutics · 2015Article
- Biochemical characterization of the interactions between doxorubicin and lipidic GM1 micelles with or without paclitaxel loading.International journal of nanomedicine · 2015Article
- Barriers to drug delivery in solid tumors.Tissue barriers · 2014Review
- Transdermal delivery of adriamycin to transplanted ehrlich ascites tumor in mice.Pharmaceutics · 2013Article
- Liposomal Doxorubicin in the treatment of breast cancer patients: a review.Journal of drug delivery · 2013Article
- Immunoconjugates and long circulating systems: origins, current state of the art and future directions.Advanced drug delivery reviews · 2013Review
- Nanocarriers for diagnosis and targeting of breast cancer.BioMed research international · 2013Review
- Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- The treatment of breast cancer using liposome technology.Journal of drug delivery · 2012Article
- Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.PloS one · 2012Article
- Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids.Molecular pharmaceutics · 2010Article
- Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin.Journal of controlled release : official journal of the Controlled Release Society · 2009Article
- Cancer therapy using tumor-associated antigens to reduce side effects.Clinical and experimental medicine · 2009Review
- Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic.Critical reviews in therapeutic drug carrier systems · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A mucocutaneous reaction in mice associated with Doxil treatment was identified as auricular erythema (AE). Given that the immuno-targeting of Doxil to tumors was found to influence also its systemic biodistribution pattern, the attempt was made to exploit a specific targeting of Doxil to reduce the manifestation of this adverse reaction. This problem is of general significance, since cutaneous reactions often lead to alterations of Doxil dosing regimen in patients and might subsequently compromise the therapeutic outcome of cancer treatment. Tumor-bearing mice were used to study the biodistribution and skin-tissue accumulation effects of the tumor-targeted Doxil (the clinically used anti-cancer formulation) coupled with the anti-cancer monoclonal 2C5 antibody (mAb 2C5) as well as AE caused by Doxil application. The modification of Doxil with mAb 2C5 resulted in a significant decrease in the normal skin accumulation of doxorubicin compared to original Doxil and substantially reduced AE. The frequency of AE was decreased by three to fourfold with the mAb 2C5-modified doxorubicin-loaded long-circulating liposomes. Thus, targeting of Doxil with the anti-cancer mAb 2C5 not only can increase the tumor-specific accumulation of the drug, but also diminishes the cutaneous side effect of the original Doxil therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.